KR20130089271A - Ｔｗｅａｋ 및 ｆｎ14 활성을 조절하는 방법 및 조성물 - Google Patents

Ｔｗｅａｋ 및 ｆｎ14 활성을 조절하는 방법 및 조성물 Download PDF

Info

Publication number
KR20130089271A
KR20130089271A KR1020137015784A KR20137015784A KR20130089271A KR 20130089271 A KR20130089271 A KR 20130089271A KR 1020137015784 A KR1020137015784 A KR 1020137015784A KR 20137015784 A KR20137015784 A KR 20137015784A KR 20130089271 A KR20130089271 A KR 20130089271A
Authority
KR
South Korea
Prior art keywords
tweak
antibody
receptor
cells
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137015784A
Other languages
English (en)
Korean (ko)
Inventor
아비 제이. 아쉬케나지
헤더 매커
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36953868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20130089271(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20130089271A publication Critical patent/KR20130089271A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020137015784A 2005-03-07 2006-03-02 Ｔｗｅａｋ 및 ｆｎ14 활성을 조절하는 방법 및 조성물 Withdrawn KR20130089271A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65933905P 2005-03-07 2005-03-07
US60/659,339 2005-03-07
PCT/US2006/007547 WO2006096487A2 (en) 2005-03-07 2006-03-02 Methods and compositions for modulating tweak and fn14 activity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077020346A Division KR20070108537A (ko) 2005-03-07 2006-03-02 Ｔｗｅａｋ 및 ｆｎ14 활성을 조절하는 방법 및 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR20157002807A Division KR20150031459A (ko) 2005-03-07 2006-03-02 Ｔｗｅａｋ 및 ｆｎ14 활성을 조절하는 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20130089271A true KR20130089271A (ko) 2013-08-09

Family

ID=36953868

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020137015784A Withdrawn KR20130089271A (ko) 2005-03-07 2006-03-02 Ｔｗｅａｋ 및 ｆｎ14 활성을 조절하는 방법 및 조성물
KR1020077020346A Withdrawn KR20070108537A (ko) 2005-03-07 2006-03-02 Ｔｗｅａｋ 및 ｆｎ14 활성을 조절하는 방법 및 조성물
KR20157002807A Ceased KR20150031459A (ko) 2005-03-07 2006-03-02 Ｔｗｅａｋ 및 ｆｎ14 활성을 조절하는 방법 및 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020077020346A Withdrawn KR20070108537A (ko) 2005-03-07 2006-03-02 Ｔｗｅａｋ 및 ｆｎ14 활성을 조절하는 방법 및 조성물
KR20157002807A Ceased KR20150031459A (ko) 2005-03-07 2006-03-02 Ｔｗｅａｋ 및 ｆｎ14 활성을 조절하는 방법 및 조성물

Country Status (12)

Country Link
US (2) US20080286271A1 (enExample)
EP (1) EP1853312B1 (enExample)
JP (2) JP2008531746A (enExample)
KR (3) KR20130089271A (enExample)
CN (2) CN101171035A (enExample)
AU (1) AU2006220825A1 (enExample)
BR (1) BRPI0608012A2 (enExample)
CA (1) CA2597485A1 (enExample)
IL (1) IL185180A0 (enExample)
RU (1) RU2007137060A (enExample)
WO (1) WO2006096487A2 (enExample)
ZA (1) ZA200707489B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004590B1 (ru) 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
AU2003224950B2 (en) 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions
WO2006088890A2 (en) * 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
CN101171035A (zh) * 2005-03-07 2008-04-30 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006130374A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Tweak binding antibodies
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2008048924A2 (en) * 2006-10-16 2008-04-24 Biogen Idec Ma Inc. Biomarkers of multiple sclerosis
EP2545938A1 (en) * 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Therapeutic use of anti-tweak receptor antibodies
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US20120055055A1 (en) * 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
BR112013007293A2 (pt) * 2010-10-05 2016-06-14 Hoffmann La Roche anticorpos contra a tweak de seres humanos e suas utilizações
US8609818B2 (en) 2011-03-10 2013-12-17 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN105779576B (zh) * 2014-12-25 2025-01-17 中国人民解放军第四军医大学 人tnfrsf12a基因的用途及其相关药物
US10994017B2 (en) 2016-12-02 2021-05-04 Avelas Biosciences, Inc. Nerve labeling compositions and uses thereof
TWI843763B (zh) * 2018-10-31 2024-06-01 日商安斯泰來製藥股份有限公司 抗人類Fn14抗體

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513626A (ja) * 1997-02-12 2001-09-04 アボツト・ラボラトリーズ 疾患の治療及び診断のために有用なｔｎｆファミリーのメンバー
EA004590B1 (ru) * 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
PT1623990E (pt) * 1999-03-08 2008-03-18 Genentech Inc Composições e métodos para o tratamento de tumores
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US6727225B2 (en) * 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
CA2394015C (en) * 1999-12-20 2013-11-05 Immunex Corporation Tweak receptor
AU8901901A (en) * 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP1811838A4 (en) * 2004-11-08 2009-07-22 Univ Maryland TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH
CN101171035A (zh) * 2005-03-07 2008-04-30 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物

Also Published As

Publication number Publication date
IL185180A0 (en) 2008-12-29
AU2006220825A1 (en) 2006-09-14
WO2006096487A3 (en) 2007-09-13
CN101171035A (zh) 2008-04-30
KR20070108537A (ko) 2007-11-12
BRPI0608012A2 (pt) 2009-11-03
ZA200707489B (en) 2008-12-31
US20080286271A1 (en) 2008-11-20
CN102225200A (zh) 2011-10-26
JP2014111605A (ja) 2014-06-19
AU2006220825A2 (en) 2006-09-14
KR20150031459A (ko) 2015-03-24
RU2007137060A (ru) 2009-04-20
EP1853312B1 (en) 2014-12-10
JP2008531746A (ja) 2008-08-14
CA2597485A1 (en) 2006-09-14
WO2006096487A2 (en) 2006-09-14
EP1853312A2 (en) 2007-11-14
US20120269808A1 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
US20120269808A1 (en) Methods and compositions for modulating tweak and fn14 activity
JP4509570B2 (ja) ヒトｄｒ４抗体及びその使用法
US20080171036A1 (en) Taci antibodies and uses thereof
US20090202531A1 (en) Uses of anti-cd40 antibodies
US8926979B2 (en) Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies
JP2005517021A5 (enExample)
JP2005510208A (ja) ＴＡＣＩｓ及びＢＲ３ポリペプチドとその用途
JP2008500969A (ja) Ｄｒ５抗体とその使用法
BR112012024713B1 (pt) anticorpo humanizado, seus usos e composição farmacêutica que o compreende
AU2016238953A1 (en) Methods and compositions for modulating TWEAK and FN14 activity
AU2012211353A1 (en) Methods and compositions for modulating TWEAK and FN14 activity
AU2014268213A1 (en) Methods and compositions for modulating TWEAK and FN14 activity
MX2007010917A (es) Metodos y composiciones para modular la actividad de tweak y fn14
HK1081560A (en) Taci antibodies and uses thereof
HK1065323B (en) Human dr4 antibodies and uses thereof
HK1107107A (en) Dr5 antibodies and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20130618

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130718

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130925

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20140730

Patent event code: PE09021S02D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150202

Application number text: 1020077020346

Filing date: 20070906

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20150203

WITB Written withdrawal of application